![]() ![]() These include relatively new approvals such as Sunosi, a treatment for excessive daytime sleepiness in patients with narcolepsy, as well as a trio of oncology products: Rylaze, Xywav, and Zepzelca. The company boasts other exciting medicines as well. But the great thing about Jazz Pharma's business is that it isn't solely a cannabis play. Nabiximols could also contribute meaningfully to the company's top line in the future if it earns approval in the U.S. The company thinks Epidiolex, which is also approved in Europe, has blockbuster potential. In the third quarter, the former generated sales of $160.4 million, 21% higher than the year-ago period. Jazz Pharma has high hopes for both Epidiolex and nabiximols. In November, management said the company could potentially file a regulatory submission for nabiximols within 18 to 24 months, if all goes according to plan. The company plans to release data from one of these studies during the first half of the year. yet but is undergoing a trio of late-stage clinical trials as a potential treatment for spasticity (muscle stiffness) related to multiple sclerosis. ![]() Jazz Pharma also now owns nabiximols, another CBD-based medicine that isn't approved in the U.S. In 2018, Epidiolex became the first CBD-based drug to be approved by the U.S. First, there is Epidiolex, which treats seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome - both of which are rare forms of epilepsy that are usually diagnosed at a very young age. The combined entity owns a couple of exciting products in this niche. GW Pharma focuses on developing cannabidiol (CBD)-derived medicines. Last year, it dove headfirst into the cannabis industry with its May 2021 acquisition of GW Pharmaceuticals, in a cash and stock transaction valued at $7.2 billion. Jazz Pharma is a biotech that was founded in 2003. The case for investing in this top marijuana stock and holding onto it looks strong for those willing to hold onto its shares for a while, despite its recent woes on the market. On top of that, Trulieve Cannabis is consistently profitable and trades at reasonable levels. The company's acquisition of Harvest Health and Recreation, which expanded its network, will help it make headway in the pot market in the U.S. Trulieve Cannabis is the leader in Pennsylvania, Arizona, and Florida, and it holds a 50% share of the market in the Sunshine State. The company currently offers a forward price-to-earnings (P/E) of 14.95, compared to a forward P/E of 16.6 for the sector. Many pot companies in North America struggle to show green on the bottom line at all, but Trulieve Cannabis has now done it for 15 consecutive reporting periods.įurthermore, after its poor showing on the stock market over the past 12 months, Trulieve Cannabis' shares have gotten a lot cheaper. In the third quarter, its revenue jumped by 64% to $224.1 million, while its net income came in at $18.6 million, 7% higher than the year-ago period. Here's one more thing to appreciate about Trulieve Cannabis: The company's recurrent profits. The combined entity has a presence in 11 states in the U.S., with 155 dispensaries as of the end of the third quarter, which made Trulieve Cannabis the leader among pot companies in this category at the time. Harvest Health and Recreation, based in Arizona, does business primarily in the West and Northeast of the country. One pot grower with solid footprints across the country is Trulieve Cannabis, which produces and sells various cannabis products.Īlthough it is best known for its leadership presence in the state of Florida, it recently expanded its reach thanks to the acquisition of Harvest Health and Recreation in an all-stock transaction valued at $2.1 billion the deal closed in October. states seem better positioned to profit from the long-term tailwind the industry will experience. Trulieve CannabisĬannabis dispensary operators with an already strong presence across many U.S. In other words, this high-growth industry presents attractive long-term opportunities, and two of the best companies to cash in on it are Trulieve Cannabis (OTC: TCNNF) and Jazz Pharmaceuticals (NASDAQ: JAZZ). Still, the pot market in North America will expand at a compound annual growth rate of 16.6% through 2028, according to some estimates. The Horizons Marijuana Life Sciences ETF, an industry benchmark, has dropped by a little more than 50% over the past 12 months, and many of the top players in the sector didn't do much better. The cannabis industry performed horribly in 2021. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |